Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) i...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
31 January 2020
|
| In: |
npj vaccines
Year: 2020, Jahrgang: 5, Pages: 1-15 |
| ISSN: | 2059-0105 |
| DOI: | 10.1038/s41541-020-0160-2 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41541-020-0160-2 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41541-020-0160-2 
|
| Verfasserangaben: | Antje Blank, Kristin Fürle, Anja Jäschke, Gerd Mikus, Monika Lehmann, Johannes Hüsing, Kirsten Heiss, Thomas Giese, Darrick Carter, Ernst Böhnlein, Michael Lanzer, Walter E. Haefeli and Hermann Bujard |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693999633 | ||
| 003 | DE-627 | ||
| 005 | 20230817164608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200403s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41541-020-0160-2 |2 doi | |
| 035 | |a (DE-627)1693999633 | ||
| 035 | |a (DE-599)KXP1693999633 | ||
| 035 | |a (OCoLC)1341313642 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Blank, Antje |e VerfasserIn |0 (DE-588)1061215962 |0 (DE-627)805162364 |0 (DE-576)174275722 |4 aut | |
| 245 | 1 | 0 | |a Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial |c Antje Blank, Kristin Fürle, Anja Jäschke, Gerd Mikus, Monika Lehmann, Johannes Hüsing, Kirsten Heiss, Thomas Giese, Darrick Carter, Ernst Böhnlein, Michael Lanzer, Walter E. Haefeli and Hermann Bujard |
| 264 | 1 | |c 31 January 2020 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.04.2020 | ||
| 520 | |a A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) in combination with GLA-SE adjuvant. | ||
| 700 | 1 | |a Fürle, Kristin |e VerfasserIn |0 (DE-588)1207554316 |0 (DE-627)1694028569 |4 aut | |
| 700 | 1 | |a Jäschke, Anja |e VerfasserIn |0 (DE-588)1143869311 |0 (DE-627)1003424384 |0 (DE-576)495193054 |4 aut | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 700 | 1 | |a Lehmann, Monika |e VerfasserIn |0 (DE-588)1141195305 |0 (DE-627)898948606 |0 (DE-576)494247568 |4 aut | |
| 700 | 1 | |a Hüsing, Johannes |d 1965- |e VerfasserIn |0 (DE-588)124519687 |0 (DE-627)36339270X |0 (DE-576)294211306 |4 aut | |
| 700 | 1 | |a Heiss, Kirsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Giese, Thomas |d 1962- |e VerfasserIn |0 (DE-588)143133543 |0 (DE-627)704399075 |0 (DE-576)333724496 |4 aut | |
| 700 | 1 | |a Carter, Darrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Böhnlein, Ernst |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lanzer, Michael |e VerfasserIn |0 (DE-588)1065643314 |0 (DE-627)816506736 |0 (DE-576)165563826 |4 aut | |
| 700 | 1 | |a Haefeli, Walter E. |d 1958- |e VerfasserIn |0 (DE-588)124572359 |0 (DE-627)656806141 |0 (DE-576)340514221 |4 aut | |
| 700 | 1 | |a Bujard, Hermann |d 1934-2020 |e VerfasserIn |0 (DE-588)1012799999 |0 (DE-627)699791324 |0 (DE-576)345952278 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t npj vaccines |d [London] : Nature Publishing Group, 2016 |g 5(2020), Artikel-ID 10, Seite 1-15 |h Online-Ressource |w (DE-627)87811839X |w (DE-600)2882262-6 |w (DE-576)482759011 |x 2059-0105 |7 nnas |a Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial |
| 773 | 1 | 8 | |g volume:5 |g year:2020 |g elocationid:10 |g pages:1-15 |g extent:15 |a Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41541-020-0160-2 |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41541-020-0160-2 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200403 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1012799999 |a Bujard, Hermann |m 1012799999:Bujard, Hermann |d 700000 |d 706000 |e 700000PB1012799999 |e 706000PB1012799999 |k 0/700000/ |k 1/700000/706000/ |p 13 |y j | ||
| 998 | |g 124572359 |a Haefeli, Walter E. |m 124572359:Haefeli, Walter E. |d 910000 |d 910100 |e 910000PH124572359 |e 910100PH124572359 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 998 | |g 1065643314 |a Lanzer, Michael |m 1065643314:Lanzer, Michael |d 910000 |d 911700 |e 910000PL1065643314 |e 911700PL1065643314 |k 0/910000/ |k 1/910000/911700/ |p 11 | ||
| 998 | |g 143133543 |a Giese, Thomas |m 143133543:Giese, Thomas |d 910000 |d 911600 |e 910000PG143133543 |e 911600PG143133543 |k 0/910000/ |k 1/910000/911600/ |p 8 | ||
| 998 | |g 124519687 |a Hüsing, Johannes |m 124519687:Hüsing, Johannes |d 910000 |d 913000 |e 910000PH124519687 |e 913000PH124519687 |k 0/910000/ |k 1/910000/913000/ |p 6 | ||
| 998 | |g 1141195305 |a Lehmann, Monika |m 1141195305:Lehmann, Monika |p 5 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |e 910000PM110903137 |e 910100PM110903137 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1143869311 |a Jäschke, Anja |m 1143869311:Jäschke, Anja |p 3 | ||
| 998 | |g 1207554316 |a Fürle, Kristin |m 1207554316:Fürle, Kristin |d 910000 |d 911700 |e 910000PF1207554316 |e 911700PF1207554316 |k 0/910000/ |k 1/910000/911700/ |p 2 | ||
| 998 | |g 1061215962 |a Blank, Antje |m 1061215962:Blank, Antje |d 910000 |d 910100 |e 910000PB1061215962 |e 910100PB1061215962 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1693999633 |e 3618350562 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1693999633","note":["Gesehen am 03.04.2020"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial","title_sort":"Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial"}],"language":["eng"],"person":[{"family":"Blank","display":"Blank, Antje","given":"Antje","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Kristin","display":"Fürle, Kristin","family":"Fürle"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Anja","display":"Jäschke, Anja","family":"Jäschke"},{"given":"Gerd","roleDisplay":"VerfasserIn","role":"aut","display":"Mikus, Gerd","family":"Mikus"},{"family":"Lehmann","display":"Lehmann, Monika","given":"Monika","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Hüsing","role":"aut","roleDisplay":"VerfasserIn","given":"Johannes","display":"Hüsing, Johannes"},{"display":"Heiss, Kirsten","role":"aut","roleDisplay":"VerfasserIn","given":"Kirsten","family":"Heiss"},{"display":"Giese, Thomas","given":"Thomas","roleDisplay":"VerfasserIn","role":"aut","family":"Giese"},{"display":"Carter, Darrick","roleDisplay":"VerfasserIn","role":"aut","given":"Darrick","family":"Carter"},{"family":"Böhnlein","display":"Böhnlein, Ernst","given":"Ernst","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Lanzer","display":"Lanzer, Michael","role":"aut","roleDisplay":"VerfasserIn","given":"Michael"},{"family":"Haefeli","roleDisplay":"VerfasserIn","role":"aut","given":"Walter E.","display":"Haefeli, Walter E."},{"family":"Bujard","display":"Bujard, Hermann","given":"Hermann","role":"aut","roleDisplay":"VerfasserIn"}],"relHost":[{"title":[{"title":"npj vaccines","title_sort":"npj vaccines"}],"name":{"displayForm":["published in partnership with the Sealy Center for Vaccine Development"]},"origin":[{"publisherPlace":"[London]","dateIssuedDisp":"28 July 2016-","publisher":"Nature Publishing Group"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"disp":"Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trialnpj vaccines","id":{"eki":["87811839X"],"zdb":["2882262-6"],"issn":["2059-0105"]},"note":["Gesehen am 30.01.2017"],"part":{"volume":"5","text":"5(2020), Artikel-ID 10, Seite 1-15","pages":"1-15","year":"2020","extent":"15"},"recId":"87811839X","pubHistory":["1, article number 16001 (July 2016)-1, article number 16022 (December 2016) ; 2, article number 1 (January 2017)-"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"id":{"doi":["10.1038/s41541-020-0160-2"],"eki":["1693999633"]},"name":{"displayForm":["Antje Blank, Kristin Fürle, Anja Jäschke, Gerd Mikus, Monika Lehmann, Johannes Hüsing, Kirsten Heiss, Thomas Giese, Darrick Carter, Ernst Böhnlein, Michael Lanzer, Walter E. Haefeli and Hermann Bujard"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"31 January 2020"}],"physDesc":[{"extent":"15 S."}]} | ||
| SRT | |a BLANKANTJEIMMUNIZATI3120 | ||